Obstetrics & Gynecology

News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Mapping Human Bone Marrow Yields New Tool, Insights on Blood Cancer

cells stained blue, green and magenta

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, compares the physical locations and morphometric (size and shape) characteristics of every hematopoietic cell in the patient’s bone marrow sample with those in healthy bone marrow, to generate a score that reflects disease severity.

Myelodysplastic neoplasms (MDS) is a form of blood cancer that usually affects older adults. About one-third of patients progress to a more aggressive cancer called acute myeloid leukemia. MDS patients must undergo frequent biopsies to identify signs of remission or worsening disease. 

headshot of a man

Dr. Sanjay Patel

Tumor Organoid Tech Advances Toward a Sci-Fi Future

clumps of cells stained blue and pink

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.

headshot of a woman

Dr. M. Laura Martin

$2.5 Million Department of Defense Grant Funds Development of Targeted Therapy for Triple-Negative Breast Cancer

Triple-negative breast cancer cell

Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers. The highly competitive DoD Breast Cancer Research Program Breakthrough Award supports innovative projects with strong potential to transform breast cancer treatment.

Triple-negative breast cancer lacks three proteins—estrogen receptor, progesterone receptor and HER2—that many of today's targeted therapies attack, leaving many patients limited to chemotherapy as their primary treatment option.

Dr. Xiaojing Ma

Dr. Xiaojing Ma

Contact Us